Audio Journal of Oncology Podcast

Jonathan T. Yang MD PhD: Radiosensitizer Shows Early Clinical Promise to Support Glioblastoma Radiotherapy 18.09.2025 10:59 ↓

Jonathan T Yang, MD, PhD

Heather McArthur MD MPH: Adjuvant Checkpoint Inhibition: Did Not Improve Survival in Patients with Triple-Negative Breast Cancer 17.09.2025 10:06 ↓

Heather McArthur MD MPH

Stefan Paepke MD: An End to “Jumping Breasts” with Mesh Supported Pre-Pectoral Breast Implants 16.09.2025 10:48 ↓

Stefan Paepke MD

Sophie Bosma MD PhD:“Young Boost” Trial Finds Low-Dose Radiation Boost Optimal for Young Patients with High-Risk Early Breast Cancer 15.09.2025 8:46 ↓

Sophie Bosma MD PhD

Adri Voogd PhD: Ductal Carcinoma in Situ: Good Outcomes from Breast Conserving Therapy, but Benefits, Risks, Costs Still Need to be Optimized 12.09.2025 15:54 ↓

Adri Voogd PhD

Annemiek van Hemert MD PhD: “Breast Cancer: MARI Node Marker Helps Most Patients with Extensive Nodal Disease Safely Avoid Axillary Lymph Node Dissection” 11.09.2025 10:16 ↓

Annemiek van Hemert MD PhD

Tim Rattay MBChB PhD: Artificial Intelligence Tool Minimizes Arm Lymphedema After Breast Cancer Surgery and Radiotherapy 10.09.2025 14:05 ↓

Tim Rattay MBChB PhD

Yasmin Civil MD PhD: Low-Risk ER+ Breast Cancer: ABLATIVE Trial Finds Marked Benefit from MRI-Guided Single-Dose Neoadjuvant Partial Breast Radiotherapy 08.09.2025 9:13 ↓

Partial breast irradiation, given before breast-conserving surgery, achieved durable pathologic complete remissions in low-risk breast cancer, and even held out the prospect of surgery-free treatment

Neo-Adjuvant Pembrolizumab Improved Outcomes with High-Risk ER+ HER2- Early Breast Cancer 02.09.2025 8:55 ↓

Heather McArthur MD MPH

Laura J. van 't Veer, PhD 28.08.2025 15:48 ↓

ImPrintTN single-sample classifier identifies no benefit from deoadjuvant pembroliozumab in TNBC

Érica A. Oliveira PhD: How to Overcome Drug Resistance: Patient Derived Organoids Study Finds Epigenetic Pathways in Colorectal Cancer 22.08.2025 24:30 ↓

Patient Derived Organoids Shine a Light on Epigenetic Archetypes as Key Drivers of Cancer Drug Resistance LONDON, UK—How to stay ahead with treatment as cancer cells evolve to evade therapies and regi

Christian Singer MD: Neoadjuvant Olaparib Combination Beats Standard of Care in Patients with Homologous Recombination Deficient BRCA 1/2-Positive Triple-Negative Breast Cancer 05.08.2025 10:32 ↓

Homologous Repair Deficient Triple Negative Breast Cancer Positive for BRCA1/2 Mutations Better with Neoadjuvant Olaparib + Carboplatin

Erica L. Mayer MD MPH: Adjuvant Abemaciclib: Start Low, then Dose Escalate in Early-stage HR+/HER2- Breast Cancer: TRADE Study Findings 18.07.2025 9:29 ↓

Interview with Erica L. Mayer MD MPH, Director of Breast Cancer Clinical Research, Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA. With comment from: Pat Price MD, Imperial College

Patients with Early-Stage Non-Squamous Non-Small Cell Lung Cancer Who can Benefit from Adjuvant Chemotherapy 12.07.2025 11:41 ↓

An interview with: David R Spigel FASCO, MD, Chief Scientific Officer, Sarah Cannon Research Institute, Nashville, Tennessee, US With comment from: Luis G Paz-Ares MD PhD Chair of Medical Oncology, Ho

Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers 03.07.2025 10:00 ↓

“Adjuvant nivolumab added to chemoradiotherapy after surgery provided a statistically and clinically meaningful disease-free survival improvement in PD-L1 all-comers patients. This is the first time i

Luis G Paz-Ares MD PhD 30.06.2025 11:51 ↓

Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)

Elena Elez, Barcelona, ASCO: BRAF Inhibitor Encorafenib Delays Progression, Extends Survival in Patients with Inoperable BRAF V600E Mutant Colorectal Cancer 19.06.2025 15:34 ↓

An interview with: Elena Elez MD PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain CHICAGO, USA—Adding the BRAF inhibitor encorafenib (partnered with EGFR-inhibitor cetuximab) to standa

Yelena Y. Janjigian MD 17.06.2025 4:49 ↓

Yelena Y. Janjigian MD says that perioperative anti-PD-L1 immunotherapy with durvalumab was a “game changer” meriting use as a new standard of care when used together with chemotherapy to

Christopher Booth MD: Post-Surgery Exercise Therapy Reduced Recurrence Risk and Extended Life in Patients with Colon Cancer 12.06.2025 10:40 ↓

Exercise was as good as the addition of a drug among patients with high risk stage 2 or stage 3 colon cancer after curative surgery, extending life and preventing cancer recurrence. Christopher Booth

Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy 10.06.2025 7:24 ↓

An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon

Andy Zeng, Toronto: Transcriptome Map Key to Malignant Transformation in AML 22.05.2025 15:01 ↓

Andy Zeng, Toronto: Transcriptome Map Key to Malignant Transformation in AML

Yelena Y Janjigian MD: PD-1 Blockade Directed by ctDNA Delayed Recurrence in Mismatch Repair Deficient Solid Tumors After Surgery and Standard of Care 13.05.2025 9:47 ↓

Yelena Y Janjigian MD talks about the use of ctDNA to direct immunotherapy among patients with mismatch repair deficient solid tumors.

Paolo Marchetti MD: Tissue or Liquid Biopsy?  Both Together Could Be Best for Advanced Solid Tumor Therapy Planning 09.05.2025 9:54 ↓

Paolo Marchetti MD, Scientific Director, Istituto Dermatopatico dell’Immacolata, Rome

Patients with Relapsed or Refractory Acute Myeloid Leukemia have Remissions with “Logic Gated”  Off-the-Shelf Natural Killer Cell Therapy 08.05.2025 14:12 ↓

An Interview with: Stephen Strickland, Jr. MD MSCI, Director, Leukemia Research; Executive Chair, Leukemia Research Committee, Sarah Cannon Research Instiute, Nashville, Tennessee USA CHICAGO – Severa

More Breast Cancer Cases in Younger Women since 2010 But Fewer Deaths 07.05.2025 14:50 ↓

An interview with: Adetunji T. Toriola, MD, PhD, MPH, Professor of Surgery, Department of Surgery and Division of Public Health Sciences, Washington University School of Medicine and Siteman Cancer Ce